Quest PharmaTech, Inc.
Quest PharmaTech, Inc. is a biotechnology company, which is engaged in the development of portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy, radioimmunotherapy and immunoadjuvants. It is also developing a series of products for the treatment of cancer and dermatological conditions, based on its SonoLight Technology platform. Its lead product candidate, Oregovomab, an immunotherapeutic product which is used for the treatment of ovarian cancer is currently undergoing a multi-center Phase IIb clinical trial in Italy. The company was founded in 1996 and is headquartered in Edmonton, Canada.